The Competitive Grant Program – Pfizer Internal Review Process supports independent medical education initiatives focused on enhancing understanding of the mechanism of action of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases in alopecia areata. This grant opportunity invites qualified educational providers to develop and deliver a comprehensive program targeted at dermatologists and healthcare professionals across the United States. A key objective is to address the knowledge gap regarding the specific role of TEC family kinases in alopecia areata.

Funding and Benefits

Individual project requests up to $100,000 USD will be considered. The estimated total available budget for this RFP is $200,000 USD. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. The maximum project length is one year.

Eligibility

Eligible applicants include medical, nursing, allied health, and pharmacy professional schools; healthcare institutions; professional organizations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education or healthcare improvement. Only organizations are eligible to receive grants. The project lead must be an employee or contractor of the requesting organization. The requesting organization must be legally able to receive award funding directly from Pfizer Inc. For projects offering continuing education credit, the requesting organization must be accredited.

Research Areas and Activities

Proposals should focus on the following areas:

• An overview of alopecia areata and current treatment paradigms.
• Dual inhibition of JAK3 and TEC family kinases in alopecia areata.
• An in-depth focus on the TEC kinase family role and the therapeutic benefit of targeting this pathway in alopecia areata treatment.

All materials must be scientifically accurate, up-to-date, and aligned with current research. Proposals should implement mechanisms to evaluate program effectiveness and participant learning outcomes. Both accredited and non-accredited programs are eligible. Please note that this RFP does not support clinical research projects or projects evaluating the efficacy of therapeutic or diagnostic agents.

Application Process

Applications must be submitted through the online portal at www.cybergrants.com/pfizer/knowledge. First-time users should create a password prior to the submission deadline. To apply, click the "Start A New Knowledge Gap Application" button. In the application, select "Yes" for the "Competitive Grant?" question, select "Dermatology - Alopecia Areata – KG" as the Primary Area of Interest, and select "2026 I&I US Dermato JAK3 and TEC IME" as the Competitive Grant Program Name. Applicants must upload a project proposal in the General RFP Submission field. The proposal should be single-spaced, using Calibri 12-point font and 1-inch margins, and must not exceed 15 pages (exclusive of references).

Deadline and Timeline

• RFP Release Date: 30 March 2026
• Submission Deadline: 25 May 2026 (23:59 Eastern Standard Time)
• Anticipated Grant Award Notification: 16 July 2026
• Anticipated Project Start Date: October 2026
• Anticipated Project End Date: October 2027

Applications submitted after the due date will not be reviewed.

Contact Information

For questions regarding this RFP, direct inquiries in writing to the Grant Officer, Talita Honorato-Rzeszewicz, at talita.honorato-rzeszewicz@pfizer.com with the subject line "2026 I&I US Dermato JAK3 and TEC IME". For technical difficulties with the CyberGrants website, use the "Technical Questions" link at the bottom of the page.